These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23797004)

  • 1. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
    Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
    Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
    Duijkers FAM; Gaal J; Meijerink JPP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
    Am J Pathol; 2012 Mar; 180(3):1223-1231. PubMed ID: 22203052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
    Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
    J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
    Kim EK; Kim S
    Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
    Passoni L; Longo L; Collini P; Coluccia AM; Bozzi F; Podda M; Gregorio A; Gambini C; Garaventa A; Pistoia V; Del Grosso F; Tonini GP; Cheng M; Gambacorti-Passerini C; Anichini A; Fossati-Bellani F; Di Nicola M; Luksch R
    Cancer Res; 2009 Sep; 69(18):7338-46. PubMed ID: 19723661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
    De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
    Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor.
    Lee JW; Park SH; Kang HJ; Park KD; Shin HY; Ahn HS
    Cancer Res Treat; 2018 Apr; 50(2):495-505. PubMed ID: 28546523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas.
    Subramaniam MM; Piqueras M; Navarro S; Noguera R
    Hum Pathol; 2009 Nov; 40(11):1638-42. PubMed ID: 19656550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors.
    Valent A; Guillaud-Bataille M; Farra C; Lozach F; Spengler B; Terrier-Lacombe MJ; Valteau-Couanet D; Danglot G; Lenoir GM; Brison O; Bénard J; Bernheim A
    Cancer Genet Cytogenet; 2004 Aug; 153(1):10-5. PubMed ID: 15325088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
    Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
    Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
    Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
    Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.
    Ogura T; Hiyama E; Kamei N; Kamimatsuse A; Ueda Y; Ogura K
    J Pediatr Surg; 2012 Oct; 47(10):1789-96. PubMed ID: 23084186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.
    van Gaal JC; Flucke UE; Roeffen MH; de Bont ES; Sleijfer S; Mavinkurve-Groothuis AM; Suurmeijer AJ; van der Graaf WT; Versleijen-Jonkers YM
    J Clin Oncol; 2012 Jan; 30(3):308-15. PubMed ID: 22184391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
    Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular genetic abnormalities of N-myc and C-myc in pediatric neuroblastic tumors and clinical pathologic significance].
    Cai RQ; Zhou CJ; Sun QN; Ma XL; Wang M; Li Y; Wang DY; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):299-304. PubMed ID: 24004585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
    Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
    Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
    Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
    Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.